The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT

Anticancer Research

Volumn 35, Issue 1, 2015, Pages 31-38

  Fuchs, Robert ^a   Schwach, Gert ^a   Stracke, Anika ^a   Meier Allard, Nathalie ^a   Absenger, Markus ^a   Ingolic, Elisabeth ^b   Haas, Helga Susanne ^a   Pfragner, Roswitha ^a   Sadjak, Anton ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

Apoptosis; Cell culture; Medullary thyroid carcinoma; Prazosin; Quinazolines; 1 adrenergic receptors

Indexed keywords

CASPASE 3; CASPASE 7; PRAZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CARCINOMA CELL LINE; CELL PROLIFERATION; CELL STRUCTURE; CELL VACUOLE; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; MEDULLARY THYROID CARCINOMA CELL; MICROSCOPY; WST-1 ASSAY; CARCINOMA, MEDULLARY; DRUG EFFECTS; DRUG SCREENING; METABOLISM; THYROID NEOPLASMS; TUMOR CELL LINE;

ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, MEDULLARY; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PRAZOSIN; RECEPTORS, ADRENERGIC, ALPHA-1; THYROID NEOPLASMS;

EID: 84920441963     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Leboulleux S, Baudin E, Travagli JP and Schlumberger M: Medullary thyroid carcinoma. Clin Endocrinol 61: 299-310, 2004.
2. American Thyroid Association Guidelines Task F, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M and Wells SA Jr.: Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19: 565-612, 2009.
3. Kebebew E, Ituarte PH, Siperstein AE, Duh QY and Clark OH: Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88: 1139-1148, 2000.
4. Marx SJ: Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5: 367-375, 2005.
5. Phay JE and Shah MH: Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 16: 5936-5941, 2010.
6. Borrello MG, Ardini E, Locati LD, Greco A, Licitra L and Pierotti MA: RET inhibition: implications in cancer therapy. Expert Opin Ther Tar 17: 403-419, 2013.
7. Kretschmer N, Rinner B, Deutsch AJ, Lohberger B, Knausz H, Kunert O, Blunder M, Boechzelt H, Schaider H and Bauer R: Naphthoquinones from Onosma paniculata induce cell-cycle arrest and apoptosis in melanoma Cells. J Nat Prod 75: 865-869, 2012.
8. Hofer D, Schwach G, Ghaffari Tabrizi-Wizsy N, Sadjak A, Sturm S, Stuppner H and Pfragner R: Christia vespertilionis plant extracts as novel antiproliferative agent against human neuroendocrine tumor cells. Oncol Rep 29: 2219-2226, 2013.
9. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J and Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. New Engl J Med 341: 1565-1571, 1999.
10. Caine M, Raz S and Zeigler M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Brit J Urol 47: 193-202, 1975.
11. Caine M, Perlberg S and Meretyk S: A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Brit J Urol 50: 551-554, 1978.
12. Kyprianou N, Litvak JP, Borkowski A, Alexander R and Jacobs SC: Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urology 159: 1810-1815, 1998.
13. Benning CM and Kyprianou N: Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res 62: 597-602, 2002.
14. Fuchs R, Stelzer I, Haas HS, Leitinger G, Schauenstein K and Sadjak A: The alpha1-adrenergic receptor antagonists, benoxathian and prazosin, induce apoptosis and a switch towards megakaryocytic differentiation in human erythroleukemia cells. Ann Hematol 88: 989-997, 2009.
15. Fuchs R, Schraml E, Leitinger G, Stelzer I, Allard N, Haas HS, Schauenstein K and Sadjak A: alpha1-Adrenergic drugs modulate differentiation and cell death of human erythroleukemia cells through non adrenergic mechanism. Exp Cell Res 317: 2239-2251, 2011.
16. Fuchs R, Schraml E, Leitinger G, Letofsky-Papst I, Stelzer I, Haas HS, Schauenstein K and Sadjak A: alpha1-adrenergic drugs exhibit affinity to a thapsigargin-sensitive binding site and interfere with the intracellular Ca2+ homeostasis in human erythroleukemia cells. Exp Cell Res 317: 2969-2980, 2011.
17. Fernando MA and Heaney AP: Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol 19: 3085-3096, 2005.
18. Hui H, Fernando MA and Heaney AP: The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis. Eur J Cancer 44: 160-166, 2008.
19. Siddiqui EJ, Shabbir M, Thompson CS, Mumtaz FH and Mikhailidis DP: Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved? Anticancer Res 25: 4281-4286, 2005.
20. Masachika E, Kanno T, Nakano T, Gotoh A and Nishizaki T: Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of alpha1-adrenoceptor blocking. Anticancer Res 33: 887-894, 2013.
21. Lin SC, Chueh SC, Hsiao CJ, Li TK, Chen TH, Liao CH, Lyu PC and Guh JH: Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle. Neoplasia 9: 830-839, 2007.
22. Wolf C, Lederer K, Pfragner R, Schauenstein K, Ingolic E and Siegl V: Biocompatibility of ultra-high molecular weight polyethylene (UHMW-PE) stabilized with alpha-tocopherol used for joint endoprostheses assessed in vitro. J Mater Sci 18: 1247-1252, 2007.
23. Anderson TF: Techniques for the preservation of threedimensional structure in preparing specimens for the electron microscope. Trans NY Acad Sci 13: 130-134, 1951.
24. Pfragner R, Wirnsberger G, Niederle B, Behmel A, Rinner I, Mandl A, Wawrina F, Luo J, Adamiker D, Hoger H, Ingolic E and Schauenstein K: Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I). Int J Oncol 8: 513-520, 1996.
25. Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Frank M, Schmidberger H, Raue F and Becker W: Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 57: 5309-5319, 1997.
26. Esbenshade TA, Theroux TL and Minneman KP: Increased voltage-dependent calcium influx produced by alpha 1Badrenergic receptor activation in rat medullary thyroid carcinoma 6-23 cells. Mol Pharmacol 45: 591-598, 1994.
27. Zink-Lorenz A, Komitowska J and Raue F: Norepinephrine induced calcitonin secretion in rat medullary thyroid carcinoma 6-23 cells: interaction between intracellular calcium and cAMP. Exp Clin Endocrinol Diabetes 104: 43-49, 1996.
28. Glancy B and Balaban RS: Role of mitochondrial Ca2+ in the regulation of cellular energetics. Biochemistry 51: 2959-2973, 2012.
29. Mimnaugh EG, Xu W, Vos M, Yuan X and Neckers L: Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. Mol Cancer Res 4: 667-681, 2006.
30. Morissette G, Moreau E, R CG and Marceau F: Massive cell vacuolization induced by organic amines such as procainamide. J Pharmacol Exp Ther 310: 395-406, 2004.
31. Rao VM, Zannou EA and Stella VJ: Design of tablets for the delayed and complete release of poorly water-soluble weak base drugs using SBE7M-beta-CD as a solubilizing agent. J Pharm Sci 100: 1576-1587, 2011.
32. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El-Deiry WS, Flavell RA, Fulda S, Garrido C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Jaattela M, Kepp O, Kimchi A, Klionsky DJ, Knight RA, Kornbluth S, Kumar S, Levine B, Lipton SA, Lugli E, Madeo F, Malomi W, Marine JC, Martin SJ, Medema JP, Mehlen P, Melino G, Moll UM, Morselli E, Nagata S, Nicholson DW, Nicotera P, Nunez G, Oren M, Penninger J, Pervaiz S, Peter ME, Piacentini M, Prehn JH, Puthalakath H, Rabinovich GA, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Scorrano L, Simon HU, Steller H, Tschopp J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden KH, Youle RJ, Yuan J, Zhivotovsky B and Kroemer G: Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 16: 1093-1107, 2009.
33. Hellstrom WJ, Wang R, Peterson CA, Varady JC, Gesundheit N and Sikka SC: Effects of alprostadil and prazosin on motility, viability and membrane integrity of human sperm. J Urology 159: 1559-1562, 1998.
34. Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT, Jr., Williamson JD, Leenen FH, Einhorn PT, Randall OS, Golden JS, Haywood LJ and The ACRG: Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. Curr Control Trials Cardiovasc Med 3: 10, 2002.
35. Officers A, Coordinators for the ACRGTA and Lipid-Lowering Treatment to Prevent Heart Attack T: Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama 288: 2981-2997, 2002.
36. Bilbro J, Mart M and Kyprianou N: Therapeutic value of quinazoline-based compounds in prostate cancer. Anticancer Res 33: 4695-4700, 2013.